全文获取类型
收费全文 | 1281833篇 |
免费 | 94917篇 |
国内免费 | 2369篇 |
专业分类
耳鼻咽喉 | 18238篇 |
儿科学 | 42331篇 |
妇产科学 | 37908篇 |
基础医学 | 187824篇 |
口腔科学 | 35566篇 |
临床医学 | 108932篇 |
内科学 | 252394篇 |
皮肤病学 | 26744篇 |
神经病学 | 99609篇 |
特种医学 | 50190篇 |
外国民族医学 | 369篇 |
外科学 | 198400篇 |
综合类 | 27503篇 |
现状与发展 | 2篇 |
一般理论 | 301篇 |
预防医学 | 92966篇 |
眼科学 | 29168篇 |
药学 | 98520篇 |
5篇 | |
中国医学 | 2835篇 |
肿瘤学 | 69314篇 |
出版年
2018年 | 12099篇 |
2016年 | 10287篇 |
2015年 | 11937篇 |
2014年 | 16374篇 |
2013年 | 24760篇 |
2012年 | 34059篇 |
2011年 | 36501篇 |
2010年 | 21556篇 |
2009年 | 20269篇 |
2008年 | 35377篇 |
2007年 | 38358篇 |
2006年 | 38943篇 |
2005年 | 38193篇 |
2004年 | 36632篇 |
2003年 | 35645篇 |
2002年 | 35110篇 |
2001年 | 58250篇 |
2000年 | 59736篇 |
1999年 | 50860篇 |
1998年 | 14355篇 |
1997年 | 12922篇 |
1996年 | 13157篇 |
1995年 | 12421篇 |
1994年 | 11823篇 |
1993年 | 10897篇 |
1992年 | 41079篇 |
1991年 | 40409篇 |
1990年 | 39950篇 |
1989年 | 38734篇 |
1988年 | 36152篇 |
1987年 | 35389篇 |
1986年 | 33760篇 |
1985年 | 32164篇 |
1984年 | 23939篇 |
1983年 | 20833篇 |
1982年 | 12390篇 |
1981年 | 10944篇 |
1979年 | 22654篇 |
1978年 | 15881篇 |
1977年 | 13735篇 |
1976年 | 12985篇 |
1975年 | 14203篇 |
1974年 | 16686篇 |
1973年 | 16085篇 |
1972年 | 15323篇 |
1971年 | 14235篇 |
1970年 | 13219篇 |
1969年 | 12738篇 |
1968年 | 11983篇 |
1967年 | 10481篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
目的 通过网络药理学的方法进行预测,再深一步进行动物实验验证来研究柴胡疏肝散治疗CAG的作用机制。方法 首先在TCMSP数据库中检索柴胡疏肝散的所有活性成分与药物靶点;通过收集PharmGkb、OMIM、GeneCards和DrugBank数据库中收录的慢性萎缩性胃炎的相关靶点。将药物靶点与疾病靶点进行映射筛选出交集靶点,将得到的交集靶点构建PPI网络与活性成分-共同靶点网络,并对其进行GO和KEGG富集分析。最后利用Vina软件进行分子对接实验验证,并通过免疫印迹法验证柴胡疏肝散对两种受体蛋白EGFR和STAT1的影响。结果 最终筛选得到柴胡疏肝散活性成分104个,潜在靶点238个,与慢性萎缩性胃炎的交集靶点52个;GO与KEGG富集分析分别得到2166条目和148条目,主要涉及到JAK-STAT信号通路、TNF信号通路、HIF-1信号通路等;分子对接结果显示EGFR、STAT1两个靶点能够与核心活性成分能够自发结合成较为稳定的构像;免疫印迹法实验证明柴胡疏肝散能够降低大鼠胃黏膜组织EGFR和STAT1蛋白表达。结论 通过网络药理学和实验验证,发现柴胡疏肝散可能通过调节EGFR和STAT1蛋白表达来共同调控胃黏膜细胞增殖与凋亡,进而发挥着治疗慢性萎缩性胃炎的效果,为深入进行柴胡疏肝散治疗慢性萎缩性胃炎的作用机制研究提供新思路和新方法。 相似文献
2.
3.
4.
5.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
6.
Timothy J. Cordingley Mark A.G. Wilson Kathryn M. Weston 《Health & social care in the community》2022,30(1):353-359
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children. 相似文献
7.
Proteomic Profiling of Small Extracellular Vesicles Isolated from the Plasma of Vietnamese Patients with Non-Small Cell Lung Cancer Reveals Some Potential Biomarkers 下载免费PDF全文
Thao Phuong Bui Phuong Lan LeLinh Thi Tu Nguyen Le Trung ThoThai Hong Trinh 《Asian Pacific journal of cancer prevention》2022,23(6):1893-1900
Background: Considering the poor prognosis of non-small cell lung cancer (NSCLC), the objective of this study was to examine the potential of plasma-derived vesicles as a source of lung cancer-specific proteins. Extracellular vesicle (EV) cargos are specific to the source cells, hence they have the potential of being a source of cancer-specific proteins. Methods: The proteins differently expressed in cancer were determined and derived from EVs isolated from the plasma of NSCLC patients at the National Lung Hospital. To this end, purification was done using gel filtration chromatography and ultracentrifugation. In addition, nano liquid chromatography mass spectrometry (LC–MS/MS) was used for analyzing. Results: Fifty-seven EV-derived proteins related to NSCLC were highlighted in this research. Some of them have not been addressed before, such as EEF1A1 (elongation factor 1-α1), KPNB1 (Importin subunit beta 1), SRC (proto-oncogene tyrosine-protein kinase) and ACTC1 (actin, alpha cardiac muscle 1). This list was further confirmed through a comparison with ExoCarta and Vesiclepedia. Conclusion: This study is the first work to show the involvement of several novel proteins of small EV (EEF1A1, KPNB1, SRC, and ACTC1) in the progression of NSCLC. The results suggested that they could serve as novel biomarkers for non-small cell lung cancer in the future. 相似文献
8.
9.
Platelets are needed to prevent or arrest bleeding and aggregate at the site of injury upon vascular damage. Platelets express receptors for estrogens which might affect the function of the platelets and their hemostatic ability. The aim was to identify possible differences in platelet function related to age, gender, and phases of the menstrual cycle by use of impedance aggregometry with Multiplate. In the first part of the study, platelet function was assessed in 60 healthy individuals (30 men and 30 women) in each of three age groups (20–25, 40–45, and 60–65 years). In the second part of the study, the platelet function was analyzed on four occasions during the menstrual cycle in women without oral contraceptives (OCs) (n = 17) and compared to 19 women on OCs and 18 men of similar age (20–40 years). For the women on OCs, aggregation was analyzed once during the tablet-free week and once late during the period with OCs. The men were sampled once. Women of younger age (<45 years) had significantly higher agonist-induced aggregation response than both men and post-menopausal women (60–65 years). The agonist-induced aggregation response did not differ between phases of the menstrual cycle or OC use. The results suggest that estradiol and/or progesterone affect spontaneous aggregation since it was found to be lowest in the mid-luteal phase. Spontaneous aggregation was significantly lower in women on OCs than in both men and women without OCs. Our findings indicate that fertile age is associated with higher aggregation response capacity of the platelets, possibly to prevent excessive bleeding during menstruation, but this response capacity is not altered during the menstrual cycle or by use of OCs. 相似文献
10.